Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.

Cold Spring Harbor molecular case studies - 1 Apr 2023

Croucher Danielle C, Devasia Anup Joseph, Abelman Dor D, Mahdipour-Shirayeh Ali, Li Zhihua, Erdmann Natalie, Tiedemann Rodger, Pugh Trevor J, Trudel Suzanne

Abstract excerpt

Genomic characterization of cancer has enabled identification of numerous molecular targets, which has led to significant advances in personalized medicine. However, with few exceptions, precision medicine approaches in the plasma cell malignancy multiple myeloma (MM) have had limited success, likely owing to the subclonal nature of molecular targets in this disease. Targeted therapies against FGFR3 have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Multiple Myeloma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Single-Cell Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 36639200
DOI: 10.1101/mcs.a006249
PMCID: PMC10240837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.PMID 36639200Read ↗

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical ImplicationsSemantic proximity Read ↗

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical ImplicationsSemantic proximity Read ↗

Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?Semantic proximity Read ↗

How to use new biology to guide therapy in multiple myeloma.Semantic proximity Read ↗

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass StudySemantic proximity Read ↗

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patientsSemantic proximity Read ↗

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.Semantic proximity Read ↗

Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and PromisesSemantic proximity Read ↗

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Semantic proximity Read ↗

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypesSemantic proximity Read ↗

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tidesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.